Goldline Pharmaceutical Peer Comparison
BSE: 544759
₹30.51
As on 11-Nov-2026IST
Market cap
₹29 Cr
Revenue (TTM)
₹31 Cr
P/E Ratio
7.1
P/B Ratio
1.2
Div. Yield
0 %
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
29 | 8,733 | 189 | 136 | 141 |
Revenue (₹ Cr) |
31 | 7,644 | 43 | 100 | 75 |
Net Profit (₹ Cr) |
4.12 | 191.80 | 11.89 | 5.00 | 13.03 |
Net Margin (%) |
13.20 | 2.50 | 27.57 | 4.79 | 17.12 |
RoE (%) |
39.41 | 8.35 | 57.64 | 9.53 | 25.60 |
Price to Earnings |
7.11 | 62.67 | 16.00 | 27.24 | 10.85 |
Price-To-Book |
1.22 | 4.91 | 6.30 | 2.60 | 1.99 |
Income Statement (₹ Cr)
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Operating Revenue
|
31.20 | 6,591.21 | 43.09 | 100.23 | 75.29 |
|
Total Income
|
31.20 | 6,610.45 | 43.11 | 104.35 | 76.11 |
|
Total Expenditure
|
24.12 | 6,325.26 | 23.11 | 95.56 | 61.60 |
|
EBITDA
|
7.08 | 265.96 | 19.98 | 4.67 | 13.68 |
|
Depreciation
|
0.24 | 43.29 | 1.16 | 0.65 | 0.17 |
|
EBIT
|
6.84 | 222.66 | 18.81 | 4.02 | 13.51 |
|
Interest
|
1.46 | 54.39 | 2.58 | 1.66 | 1.32 |
|
Other Income
|
0.00 | 19.24 | 0.02 | 4.12 | 0.83 |
|
Exceptional Items
|
-- | -8.18 | -- | -0.01 | -- |
|
Profit before Tax
|
5.39 | 179.34 | 16.25 | 6.47 | 13.02 |
|
Provision for Tax
|
1.27 | 33.50 | 4.37 | 1.47 | -0.01 |
|
Profit after Tax
|
4.12 | 145.84 | 11.89 | 5.00 | 13.03 |
Liabilities (₹ Cr)
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
14.25 | 1,688.61 | 26.51 | 52.48 | 71.19 |
|
Minority Interest
|
-- | 63.94 | -6.17 | -0.08 | -- |
|
Non-Current Liabilities
|
2.43 | 206.12 | 33.45 | 4.66 | 5.15 |
|
Current Liabilities
|
12.11 | 1,587.57 | 19.18 | 42.23 | 18.88 |
|
Total Liabilities
|
28.87 | 3,600.22 | 73.31 | 99.64 | 95.22 |
Assets (₹ Cr)
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2.75 | 1,037.80 | 18.31 | 23.77 | 6.26 |
|
Current Assets
|
26.05 | 2,503.13 | 54.67 | 75.53 | 88.97 |
|
Total Assets
|
28.87 | 3,600.22 | 73.31 | 99.64 | 95.22 |
|
Total Debt*
|
9.16 | 566.68 | 39.99 | 36.71 | 6.64 |
|
Net Current Assets
|
13.93 | 915.56 | 35.48 | 33.30 | 70.09 |
|
Contingent Liabilities
|
3.37 | 5.51 | -- | 0.14 | -- |
Cashflow (₹ Cr)
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2.81 | 96.20 | -6.03 | -8.61 | -1.28 |
|
Cash Flow from Investing Activities
|
-0.06 | -303.06 | -2.31 | -13.33 | -2.83 |
|
Cash from Financing Activities
|
-3.40 | 123.66 | 8.43 | 31.59 | 27.82 |
|
Net Cash Inflow / Outflow
|
-0.65 | -83.20 | 0.09 | 9.65 | 23.70 |
Ratios
Profitability Ratios
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
ROCE (%)
|
30.60 | 10.93 | 39.14 | 9.12 | 25.26 |
|
ROE (%)
|
39.41 | 8.57 | 57.64 | 9.53 | 25.60 |
|
ROA (%)
|
14.98 | 4.68 | 21.33 | 5.04 | 19.27 |
|
EBIT Margin (%)
|
22.70 | 4.33 | 46.41 | 8.77 | 19.27 |
|
Net Margin (%)
|
13.20 | 2.21 | 27.57 | 4.79 | 17.12 |
|
Cash Profit Margin (%)
|
13.97 | 2.87 | 30.29 | 5.64 | 17.54 |
Growth Ratios
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
11.20 | 29.35 | 12.45 | 0.00 | 29.20 |
|
EBIT Growth (%)
|
16.95 | 35.13 | 29.01 | -- | 54.39 |
|
Net Profit Growth (%)
|
45.26 | 35.75 | 22.50 | 0.00 | 81.11 |
|
EPS Growth (%)
|
45.26 | 21.32 | 21.40 | 0.00 | 32.67 |
|
Book Value Growth (%)
|
47.19 | -2.19 | 79.96 | 0.00 | 132.49 |
Valuation Ratios
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 47.12 | 0.00 | 25.46 | 8.49 |
|
Price / Book Value
|
0.00 | 3.22 | 0.00 | 2.43 | 1.55 |
|
Dividend Yield (%)
|
-- | 0.00 | -- | 0.00 | 0.00 |
|
EV/EBITDA
|
2.44 | 20.43 | 2.45 | 16.66 | 6.39 |
|
Market Cap (₹ Cr)
|
0.00 | 5,420.61 | 0.00 | 127.33 | 110.62 |
Solvency Ratios
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.64 | 0.34 | 1.51 | 0.70 | 0.09 |
|
Short term debt to equity ratio
|
0.42 | 0.26 | 0.22 | 0.48 | 0.01 |
|
Current Ratio
|
2.15 | 1.58 | 2.85 | 1.79 | 4.71 |
|
Quick Ratio
|
1.64 | 1.05 | 0.95 | 1.49 | 3.21 |
|
Interest Coverage
|
4.70 | 4.30 | 7.29 | 4.89 | 10.87 |
Operating Efficiency Ratios
| Goldline Pharmaceutical | Entero Health | Bio Medica Laboratories | VijayPD Ceutical | Speciality Medicines | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
51.70 | 18.39 | 25.19 | 30.52 | 35.20 |
|
Asset Turnover
|
1.13 | 2.11 | 0.77 | 1.01 | 1.11 |
|
Receivable days
|
156.90 | 56.56 | 63.33 | 111.39 | 87.52 |
|
Inventory Days
|
75.99 | 41.57 | 230.85 | 45.39 | 110.76 |
|
Payable days
|
64.86 | 34.66 | 181.09 | 32.72 | 43.45 |
|
Cash Conversion Cycle
|
168.03 | 63.47 | 113.10 | 124.06 | 154.84 |